Press release
Anaplastic Thyroid Cancer Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
Anaplastic Thyroid Cancer Overview
Anaplastic thyroid carcinoma, also known as undifferentiated thyroid carcinoma, is a rare, highly aggressive malignant tumor accounting for 2 to 3 percent of all thyroid gland neoplasms. Anaplastic thyroid carcinoma continues to be one of the most deadly diseases worldwide and carries a very poor prognosis.
"Anaplastic Thyroid Cancer Pipeline Insight, 2022" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Anaplastic Thyroid Cancer Market.
The Anaplastic Thyroid Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Anaplastic Thyroid Cancer Pipeline Report: https://www.delveinsight.com/report-store/anaplastic-thyroid-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Anaplastic Thyroid Cancer treatment therapies with a considerable amount of success over the years. Anaplastic Thyroid Cancer Key players such as - AffyImmune Therapeutics, Faron Pharmaceuticals Ltd, Codiak BioSciences, Shanghai Henlius Biotech, Taizhou Hanzhong biomedical co. LTD, Merck & Co, Takeda Oncology, and others, are developing therapies for the Anaplastic Thyroid Cancer treatment
• Anaplastic Thyroid Cancer Emerging therapies such as - AIC100, FP-1305, CDK-002, HLX208, HX008, Pembrolizumab, Sapanisertib, and others are expected to have a significant impact on the Anaplastic Thyroid Cancer market in the coming years.
• In February 2022, Stanford University in collaboration with Merck Sharp & Dohme LLC initiated a Phase II trial of Pembrolizumab in metastatic or locally advanced anaplastic/undifferentiated thyroid cancer.
Anaplastic Thyroid Cancer Pipeline Therapeutics Assessment
• Anaplastic Thyroid Cancer Assessment by Product Type
• Anaplastic Thyroid Cancer By Stage and Product Type
• Anaplastic Thyroid Cancer Assessment by Route of Administration
• Anaplastic Thyroid Cancer By Stage and Route of Administration
• Anaplastic Thyroid Cancer Assessment by Molecule Type
• Anaplastic Thyroid Cancer by Stage and Molecule Type
DelveInsight's Anaplastic Thyroid Cancer Report covers around 8+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Emerging Anaplastic Thyroid Cancer Drugs Under Different Phases of Clinical Development Include:
• AIC100: AffyImmune Therapeutics
• FP-1305: Faron Pharmaceuticals Ltd
• CDK-002: Codiak BioSciences
• HLX208: Shanghai Henlius Biotech
• HX008: Taizhou Hanzhong biomedical co. LTD
• Pembrolizumab: Merck & Co
• Sapanisertib: Takeda Oncology
Get a Free Sample PDF Report to know more about Anaplastic Thyroid Cancer Pipeline Assessment- https://www.delveinsight.com/sample-request/anaplastic-thyroid-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Anaplastic Thyroid Cancer Pipeline Analysis:
The Anaplastic Thyroid Cancer pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the Anaplastic Thyroid Cancer treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Anaplastic Thyroid Cancer Treatment.
• Anaplastic Thyroid Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Anaplastic Thyroid Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Anaplastic Thyroid Cancer market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Further Anaplastic Thyroid Cancer product details are provided in the report. Download the Anaplastic Thyroid Cancer pipeline report to learn more about the emerging Anaplastic Thyroid Cancer therapies at:
https://www.delveinsight.com/sample-request/anaplastic-thyroid-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Anaplastic Thyroid Cancer Pipeline Market Drivers
• Rising prevalence of thyroid cancer
• Improving Healthcare Infrastructure
• Demand for New and Effective Drugs
• Increasing awareness about anaplastic thyroid cancer
Anaplastic Thyroid Cancer Pipeline Market Barriers
• High cost of treatment
• Adverse effects associated with the chemotherapy
Scope of Anaplastic Thyroid Cancer Pipeline Drug Insight
• Coverage: Global
• Key Anaplastic Thyroid Cancer Companies: AffyImmune Therapeutics, Faron Pharmaceuticals Ltd, Codiak BioSciences, Shanghai Henlius Biotech, Taizhou Hanzhong biomedical co. LTD, Merck & Co, Takeda Oncology, and others
• Key Anaplastic Thyroid Cancer Therapies: AIC100, FP-1305, CDK-002, HLX208, HX008, Pembrolizumab, Sapanisertib, and others
• Anaplastic Thyroid Cancer Therapeutic Assessment: Anaplastic Thyroid Cancer current marketed and Anaplastic Thyroid Cancer emerging therapies
• Anaplastic Thyroid Cancer Market Dynamics: Anaplastic Thyroid Cancer market drivers and Anaplastic Thyroid Cancer market barriers
Request for Sample PDF Report for Anaplastic Thyroid Cancer Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/anaplastic-thyroid-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1 Anaplastic Thyroid Cancer Report Introduction
2 Anaplastic Thyroid Cancer Executive Summary
3 Anaplastic Thyroid Cancer Overview
4 Anaplastic Thyroid Cancer- Analytical Perspective In-depth Commercial Assessment
5 Anaplastic Thyroid Cancer Pipeline Therapeutics
6 Anaplastic Thyroid Cancer Late Stage Products (Phase II/III)
7 Anaplastic Thyroid Cancer Mid Stage Products (Phase II)
8 Anaplastic Thyroid Cancer Early Stage Products (Phase I)
9 Anaplastic Thyroid Cancer Preclinical Stage Products
10 Anaplastic Thyroid Cancer Therapeutics Assessment
11 Anaplastic Thyroid Cancer Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Anaplastic Thyroid Cancer Key Companies
14 Anaplastic Thyroid Cancer Key Products
15 Anaplastic Thyroid Cancer Unmet Needs
16 Anaplastic Thyroid Cancer Market Drivers and Barriers
17 Anaplastic Thyroid Cancer Future Perspectives and Conclusion
18 Anaplastic Thyroid Cancer Analyst Views
19 Appendix
20 About DelveInsight
Download Sample PDF Report to know more about Anaplastic Thyroid Cancer drugs and therapies- https://www.delveinsight.com/sample-request/anaplastic-thyroid-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Latest Reports:
Ventricular Assist Devices Market https://www.delveinsight.com/report-store/ventricular-assist-devices-vad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"DelveInsight's 'Ventricular Assist Devices (VAD) Market Insight, Competitive Landscape and Market Forecast - 2027' report delivers an in-depth understanding of Ventricular Assist Devices and the historical and forecasted Ventricular Assist Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Vein Illumination Devices Market https://www.delveinsight.com/report-store/vein-illumination-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Vein Illumination Devices - Market Insight, Competitive Landscape and Market Forecast, 2027' report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Basal Cell Carcinoma (Basal Cell Epithelioma) Market
https://www.delveinsight.com/report-store/basal-cell-carcinoma-basal-cell-epithelioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Basal Cell Carcinoma (Basal Cell Epithelioma) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Basal Cell Carcinoma (Basal Cell Epithelioma), historical and forecasted epidemiology as well as the Basal Cell Carcinoma (Basal Cell Epithelioma) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Anaplastic Thyroid Cancer Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments here
News-ID: 2823560 • Views: …
More Releases from DelveInsight Business Research
Spinocerebellar Ataxias Pipeline 2025: Comprehensive Clinical Trials and Therapi …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Spinocerebellar Ataxias pipeline constitutes 8+ key companies continuously working towards developing 10+ Spinocerebellar Ataxias treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Spinocerebellar Ataxias Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spinocerebellar Ataxias Market.
The Spinocerebellar…
Presbyopia Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight O …
The Presbyopia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Presbyopia pipeline products will significantly revolutionize the Presbyopia market dynamics.
DelveInsight's "Presbyopia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Presbyopia, historical and forecasted epidemiology as well as the Presbyopia market trends in the United States, EU5 (Germany, Spain, Italy, France,…
Idiopathic Pulmonary Fibrosis Market Insights Highlight Expanding Outlook Till 2 …
DelveInsight's "Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Idiopathic Pulmonary Fibrosis, historical and forecasted epidemiology as well as the Idiopathic Pulmonary Fibrosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Idiopathic Pulmonary Fibrosis, offering comprehensive insights into the Idiopathic Pulmonary Fibrosis revenue trends,…
Myocardial Infarction Market Positioned for Accelerated Development Through 2034 …
DelveInsight's "Myocardial Infarction Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myocardial Infarction, historical and forecasted epidemiology as well as the Myocardial Infarction market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Myocardial Infarction market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Myocardial Infarction Market Forecast
https://www.delveinsight.com/sample-request/myocardial-infarction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
More Releases for Anaplastic
Anaplastic Astrocytoma Market Outlook, Epidemiology, Landscape and Growth Trajec …
Anaplastic astrocytoma (AA) is a rare, malignant brain tumor classified as World Health Organization (WHO) Grade III glioma, characterized by its aggressive nature and poor prognosis. While not as common as glioblastoma, anaplastic astrocytoma represents a significant challenge due to its high recurrence rates, limited treatment options, and resistance to conventional therapies.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70897
Over the past decade, the treatment landscape has slowly evolved…
Anaplastic Large Cell Lymphoma Drugs Market: An In-Depth Analysis
The global Anaplastic Large Cell Lymphoma Drugs market was valued approximately USD 10.5 billion in 2022 and is projected to reach around USD 17.1 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5% during the forecast period.
Anaplastic Large Cell Lymphoma Drugs Market Overview
Anaplastic Large Cell Lymphoma is a rare type of non-Hodgkin lymphoma characterized by the proliferation of large lymphoid cells. The market for ALCL…
Anaplastic Astrocytoma Market Development, Trends, Segmentations Analysis
Anaplastic astrocytoma is a very rare type of malignant brain tumor affecting human at all ages. As this tumor develops from astrocytes, the star-shaped brain cells it is termed as astrocytoma. The astrocytes along with other cells protect nerve cells in the brain and spinal cord by surrounding them. All these protective cells are collectively termed as glial cells. World Health Organization (WHO) graded these tumors on a scale from…
Anaplastic Astrocytoma - Pipeline Review, H2 2017 - Pharmaceutical Report
Anaplastic astrocytoma is a grade III tumor. It accounts for two percent of all brain tumors. It is a type of glioma that develops from star-shaped glial cells (astrocytes), which support nerve cells. Anaplastic astrocytoma grows faster and more aggressively than grade II astrocytomas. The tumor cells are not uniform in appearance and invade neighboring tissue. Symptoms include headache, weakness, clumsiness, difficulty walking and seizures. Anaplastic astrocytoma is common among…
Anaplastic Oligoastrocytoma Market Snapshot by 2024 – Persistence Market Resea …
Oligoastrocytomas is a part of a group of brain tumor called “gliomas”. Glioma tumor is originated in the brain or spine. Oligoastrocytomas contains both astrocytoma cells and oligodendroglioma. About 2.3% of the brain tumors reported are diagnosed as oligoastrocytomas. Oligoastrocytomas is divided into two parts, low grade and anaplastic. According to the WHO grading system, anaplastic oligoastrocytomas are usually identify as grade 1 and grade 2 but sometimes they appear…
Latest Report Details Of Global Anaplastic Thyroid Cancer Market
Marketresearchreports.biz has added a new research report on the "Anaplastic Thyroid Cancer-Pipeline Insights, 2017" to its collection.
DelveInsights, Anaplastic Thyroid Cancer- Pipeline Insights, 2017, report provides in depth insights on the pipeline drugs and their development activities around the Anaplastic Thyroid Cancer. The DelveInsightsReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical…
